Regional Meetings 2018

Endocrine Treatment of Metastatic Breast Cancer: An Interactive Grand Rounds Series for Nurses

Research To Practice (RTP) is pleased to offer organizations throughout the United States the opportunity to host an interactive live educational activity focused on the management of ER-positive metastatic breast cancer (mBC) for their staff and/or members. As part of this program a clinical investigator with expertise in the management of breast cancer will travel to your community to lead a 1.25-hour accredited session developed by the RTP scientific staff under the leadership of president Neil Love, MD that will feature a blend of didactic presentation, discussion of relevant clinical situations and cases, interactive polling of attendees using keypad devices and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at or call (800) 233-6153.

Learn about our Improving the Efficacy of Endocrine Treatment breast cancer CME series.

Schedule of Events:

Tuesday, August 14, 2018
6:00 PM – 7:15 PM
Education program

Rita Nanda, MD
Central Connecticut ONS Chapter
New Haven, Connecticut

Buffet dinner will be provided
Registration is open only to oncology nursing professionals from this ONS chapter and invited guests.

Email us for more information.
Tuesday, October 9, 2018
6:30 PM – 7:45 PM
Education program

Rita Nanda, MD
Metro Minnesota ONS Chapter
Minneapolis, Minnesota

Buffet dinner will be provided
Registration is open only to oncology nursing professionals from this ONS chapter and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Each 1.25-hour session will include 4 topic modules focused on the management of ER-positive mBC. Each module will employ an identical format and feature discussion of cases from the faculty members selected to depict common scenarios encountered in clinical practice (newly diagnosed ER-positive mBC, disease progression on an adjuvant aromatase inhibitor, progression on a CDK4/6 inhibitor with endocrine therapy, et cetera). Topics addressed during the session will include the following:

MODULE 1: Background — Clinical, Biologic and Pharmacologic Considerations
  • Impact of tumor phenotype on decision-making for patients with mBC
  • Incidence of and current therapeutic paradigm for ER-positive mBC
  • Mechanisms of action and resistance associated with common endocrine therapies
  • Biologic rationale for targeting the CDK4/6, mTOR and PI3 kinase pathways
MODULE 2: Efficacy, Tolerability and Practical Use of CDK4/6 Inhibitors
  • Available data with and FDA-approved indications for abemaciclib, palbociclib and ribociclib
  • Clinical role for patients with menstrual functioning, brain metastases or HER2-positive disease
  • Treatment duration, dose and schedule with CDK4/6 inhibitors
  • Monitoring for and management of common toxicities (cytopenias, gastrointestinal side effects, QT prolongation, et cetera)
  • Assessing and optimizing patient adherence to therapy with CDK4/6 inhibitors and other oral anticancer treatments
MODULE 3: First-Line Endocrine Therapy-Based Treatment of Metastatic Disease
  • Efficacy of mTOR inhibition in combination with endocrine therapy
  • Prophylaxis and treatment of everolimus-related toxicities (mucositis, pneumonitis, et cetera)
  • Sequencing of chemotherapy for patients with ER-positive, HER2-negative mBC
MODULE 4: New Approaches Under Investigation
  • Incidence and clinical relevance of estrogen receptor tumor mutations
  • Current clinical trials of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings
  • Combination strategies with CDK4/6 and mTOR inhibitors
  • Available data with and potential role of PI3K inhibitors

Each session will conclude with a 10- to 15-minute Q&A segment


Adam M Brufsky, MD, PhD
Professor of Medicine
Associate Director for Translational Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief, Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

Rita Nanda, MD
Co-Director, Breast Medical Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois

Ruth M O’Regan, MD
Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Sara M Tolaney, MD, MPH
Dana-Farber Cancer Institute
Associate Director of Clinical Research
Susan F Smith Center for Women’s Cancers
Senior Physician
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology PLLC
Nashville, Tennessee

Target Audience:
This activity is intended for oncology nurses, nurse practitioners, clinical nurse specialists and other healthcare providers involved in the treatment of ER-positive metastatic breast cancer.

Learning Objectives:

  • Describe the influence of tumor phenotype on long-term outcomes and the selection of systemic therapy for patients with advanced breast cancer (BC).
  • Discuss the benefits and risks associated with existing and recently approved systemic therapies used in the evidence-based treatment of ER-positive metastatic BC (mBC), including endocrine agents, chemotherapy regimens and biologic treatments.
  • Recognize the FDA-endorsed indications for the commercially available CDK4/6 and mTOR inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with mBC.
  • Educate patients regarding the unique side effects associated with CDK4/6 and mTOR inhibitors, and develop preventive and emergent strategies to reduce or ameliorate these toxicities.
  • Appreciate the detrimental effect of poor adherence to treatment, identify and monitor potential causes of this phenomenon and develop a plan to effectively assess and support compliance for patients receiving oral anticancer therapies.
  • Identify opportunities to enhance communication and facilitate ongoing dialogue between the oncology nurse and patients with mBC to optimize clinical and quality-of-life outcomes.

CNE Credit Form:
A CNE credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.25 contact hours is provided by Research To Practice.
This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 5 to 7 weeks.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from Lilly and Novartis.